Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05002569 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,093
- Enrollment target
NCT05002569 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 1,093 participants.
The verdict
NCT05002569, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,093 participants
- Enrollment target
Study Summary
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Nivolumab + Relatlimab Fixed Dose Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,093 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2025-04-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05002569
The ClinicalTrials.gov registry entry for NCT05002569 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,093 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT05002569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05002569 about?
NCT05002569 is a clinical study titled "A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma". The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
What is the current status of trial NCT05002569?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,093 participants. The study started on 2021-10-19. Estimated completion is 2025-04-02.
What interventions are being tested in trial NCT05002569?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Nivolumab + Relatlimab Fixed Dose Combination (BIOLOGICAL).
Who is sponsoring clinical trial NCT05002569?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.